This systematic review included randomized controlled trials involving patients of all age groups diagnosed with hypercholesterolemia, regardless of the comorbidities and underlying etiology, who are on stable statin therapy or maximally tolerated statin therapy and should have received bempedoic acid, inclisiran, or PCSK9 inhibitors as intervention. The gene discussed is PCSK9; the disease is Hypercholesterolemia.